ESR1 and breast carcinoma: This is the first biomarker analysis directly comparing patient treatment outcomes using expression data of each individual annexin and then combining the expression date of all annexins and S100A binding proteins (i.e. an annexin expression profile) in a specific sub-set of breast cancer patients (ER+p53+) within a larger cohort.